The Huntington's Drug That's Doing What Others Couldn't

SKY-0515 takes a different route. It's an oral RNA splicing modifier: a pill that changes how cells read the genetic instructions for huntingtin. Instead of cutting the message after it's made, splicing modifiers rearrange how the message gets assembled in the first place. If an ASO is like intercepting a letter at the post office, a splicing modifier rewrites the letter at the source.

The practical upside? Patients swallow a pill instead of getting a spinal tap. That alone could change who's willing to enroll in trials and, eventually, who's willing to stay on treatment for years.

Biologically, SKY-0515 also appears to be hitting its targets. At the 9 mg dose, the drug reduced mutant huntingtin protein by more than 60% and lowered PMS1 mRNA (a genetic modifier linked to disease onset) by more than 25%. Safety looked clean: no treatment-related serious adverse events were reported in the dataset.

Why Skeptics Have a Point

Before you start printing "Huntington's: Solved" t-shirts, some important caveats.

This was a small Phase 1/2 study. The comparison group wasn't randomized; it was drawn from an external database called Enroll-HD. External controls are like comparing your marathon time to your neighbor's Strava data. Useful, sure, but not the same as running side by side.

The Huntington's field has been burned specifically by the gap between encouraging biomarker results and actual clinical benefit. Tominersen lowered huntingtin protein beautifully. It still failed. Branaplam had a plausible mechanism. It still caused nerve damage. The pattern has taught everyone a painful lesson: biology isn't destiny until a placebo-controlled trial says so.

Skyhawk knows this. The company is already running FALCON-HD, a randomized, double-blind, placebo-controlled Phase 2/3 trial that enrolled 144 patients with Stage 2 and early Stage 3 Huntington's across Australia and New Zealand. That's the real test.

A Field Desperate for Good News

Right now, Huntington's patients can get drugs that manage symptoms like involuntary movements and mood changes. That's it. There is no approved therapy that slows or stops the underlying brain degeneration. The disease affects an estimated 41,000–43,000 people in the U.S. alone, with many more carrying the gene mutation and waiting to find out when symptoms will start.

Every approved treatment is essentially rearranging deck chairs. What patients need is someone to steer the ship.

Skyhawk isn't the only company still trying. PTC Therapeutics is running its own oral splicing modifier, PTC518, through Phase 2 trials for Huntington's. Roche and Novartis remain active in the broader RNA therapeutics space, though both carry the scars of their earlier Huntington's setbacks. The competitive landscape is small but real, and the first company to prove disease modification in a controlled trial could define the market.

The Bottom Line

SKY-0515's 15-month data is genuinely encouraging. A 1.59-point functional advantage, consistent results across every measured domain, solid target engagement, clean safety, and an oral route of administration: that's a compelling package for a disease that has humbled everyone who's tried.

But compelling packages have fallen apart before in Huntington's. The FALCON-HD trial will be the moment of truth. If the drug holds up against a real placebo group in a properly powered study, Skyhawk won't just have validated SKY-0515. It will have validated an entirely new way of attacking neurodegeneration.

For now, the data earns something rare in Huntington's research: cautious optimism that isn't foolish.

Roche Just Paid $36.5M for a Machine That Tests 300,000 Antibody Combos

Roche just signed a deal worth up to $1 billion with a three-year-old startup that can screen 300,000+ bispecific antibody combinations at once. The real story isn't the price tag; it's what it says about the future of drug discovery.